Alessandra Lugaresi

Summary

Affiliation: University of Chieti
Country: Italy

Publications

  1. pmc Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study
    Luisa Pastò
    Department of Neurology, University of Florence, Viale Morgagni 85, 50134, Florence, Italy
    BMC Neurol 12:165. 2012
  2. pmc Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
    Marta Giannini
    Department of Neurology, University of Florence, Florence, Italy
    BMC Neurol 12:124. 2012
  3. pmc Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
    Virginia Devonshire
    Department of Neurology, University of British Columbia, Vancouver, BC, Canada
    BMC Neurol 10:28. 2010
  4. doi RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence
    Alessandra Lugaresi
    Department of Neuroscience and Imaging, University G D Annunzio, c o Centro Sclerosi Multipla, Ospedale Clinicizzato SS Annunziata, Via dei Vestini 31, 66100 Chieti, Italy
    Expert Opin Drug Deliv 10:273-83. 2013
  5. pmc Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study
    Alessandra Lugaresi
    Department of Neuroscience and Imaging, University G, D Annunzio, Via dei Vestini 31, 66100 Chieti, Italy
    BMC Neurol 12:7. 2012
  6. pmc Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
    Valentina Durastanti
    Department of Neurological Sciences, University La Sapienza, Viale dell Universita, 30, 00185, Rome, Italy
    J Transl Med 9:42. 2011
  7. doi Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
    Alessandra Lugaresi
    University Gabriele d Annunzio of Chieti Pescara, Ospedale Clinicizzato Santissima Annunziata, c o Centro Sclerosi multipla VII livello, corpo A, Department of Oncology and Neuroscience, Chieti, Italy
    Expert Opin Drug Deliv 6:995-1002. 2009
  8. doi A computational platform for MALDI-TOF mass spectrometry data: application to serum and plasma samples
    Dante Mantini
    Istituto Tecnologie Avanzate Biomediche ITAB, Fondazione G D Annunzio, Chieti, Italy
    J Proteomics 73:562-70. 2010
  9. doi Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery
    Damiana Pieragostino
    Centro Studi sull Invecchiamento Ce S I, Fondazione G d Annunizio, Chieti, Italy
    J Proteomics 73:579-92. 2010
  10. doi Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis
    Damiana Pieragostino
    Research Centre on Aging Ce S I, University G d Annunzio of Chieti Pescara, Chieti, Italy
    Proteomics 13:1002-9. 2013

Collaborators

  • Andrea Urbani
  • Piero Del Boccio
  • Dante Mantini
  • Valentina Durastanti
  • Marinella Clerico
  • Angelo Di Iorio
  • Claudio Gasperini
  • Carlo Pozzilli
  • Stefano Sotgiu
  • Marco Onofrj
  • Damiana Pieragostino
  • Luisa Pastò
  • Marta Giannini
  • Giovanna De Luca
  • Lorenzo Razzolini
  • Laura De Giglio
  • Maria Giovanna Marrosu
  • Damiano Paolicelli
  • Lucia Moiola
  • Angelo Ghezzi
  • Bahia Hakiki
  • Rocco Totaro
  • Claudio Solaro
  • Loredana La Mantia
  • Maria Trojano
  • Maria Pia Amato
  • Francesco Patti
  • Maria Rosaria Tola
  • Elisa Piscolla
  • Giancarlo Comi
  • Vittorio Martinelli
  • Emilio Portaccio
  • Paolo Sacchetta
  • Carmine Di Ilio
  • Virginia Devonshire
  • Domenico Gambi
  • Carla Iarlori
  • Claudia Rossi
  • Viviana Greco
  • Maria Di Ioia
  • Diego Centonze
  • Luisa Pieroni
  • Diego Franciotta
  • Simona D'Aguanno
  • Gianluigi Mancardi
  • Valeria Di Tommaso
  • Gian Luigi Mancardi
  • Michael Lang
  • Francesca Petrucci
  • Txomin Arbizu
  • Bjorn Borre
  • Giorgio Federici
  • Peter Cornelisse
  • Barry Singer
  • Sara Tiberio
  • Elisabetta Verdun di Cantogno
  • Marcella Reale
  • Claudio Feliciani
  • Pio Conti
  • Antonio Tulli

Detail Information

Publications13

  1. pmc Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study
    Luisa Pastò
    Department of Neurology, University of Florence, Viale Morgagni 85, 50134, Florence, Italy
    BMC Neurol 12:165. 2012
    ..The objective of this study was to assess the impact of epidural analgesia (EA) and caesarean delivery (CD) on the risk of post-partum relapses and disability in women with MS...
  2. pmc Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
    Marta Giannini
    Department of Neurology, University of Florence, Florence, Italy
    BMC Neurol 12:124. 2012
    ....
  3. pmc Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
    Virginia Devonshire
    Department of Neurology, University of British Columbia, Vancouver, BC, Canada
    BMC Neurol 10:28. 2010
    ..This study was performed to assess the suitability of a new electronic device for the subcutaneous (sc) administration of interferon (IFN) beta-1a, 44 mcg three times weekly, for relapsing MS...
  4. doi RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence
    Alessandra Lugaresi
    Department of Neuroscience and Imaging, University G D Annunzio, c o Centro Sclerosi Multipla, Ospedale Clinicizzato SS Annunziata, Via dei Vestini 31, 66100 Chieti, Italy
    Expert Opin Drug Deliv 10:273-83. 2013
    ..As injection-related problems are common barriers to adherence, autoinjectors have been developed to improve the ease and convenience of self-injection...
  5. pmc Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study
    Alessandra Lugaresi
    Department of Neuroscience and Imaging, University G, D Annunzio, Via dei Vestini 31, 66100 Chieti, Italy
    BMC Neurol 12:7. 2012
    ..We sought to assess short-term adherence to, and tolerability of, interferon (IFN) β-1a administered via electronic autoinjection device in patients with relapsing-remitting multiple sclerosis (RRMS)...
  6. pmc Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients
    Valentina Durastanti
    Department of Neurological Sciences, University La Sapienza, Viale dell Universita, 30, 00185, Rome, Italy
    J Transl Med 9:42. 2011
    ..The aim of the study was to investigate the dynamic profile of neopterin and kyn/trp ratio in patients with relapsing remitting multiple sclerosis (RRMS) treated with two different doses of IFNβ-1a over a period of 24 months...
  7. doi Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
    Alessandra Lugaresi
    University Gabriele d Annunzio of Chieti Pescara, Ospedale Clinicizzato Santissima Annunziata, c o Centro Sclerosi multipla VII livello, corpo A, Department of Oncology and Neuroscience, Chieti, Italy
    Expert Opin Drug Deliv 6:995-1002. 2009
    ..However, the benefits offered by treatment may be compromised by suboptimal levels of adherence to prescribed regimens...
  8. doi A computational platform for MALDI-TOF mass spectrometry data: application to serum and plasma samples
    Dante Mantini
    Istituto Tecnologie Avanzate Biomediche ITAB, Fondazione G D Annunzio, Chieti, Italy
    J Proteomics 73:562-70. 2010
    ..In this work, we propose an integrated software platform, MASCAP, intended for comparative biomarker detection from MALDI-TOF MS data...
  9. doi Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery
    Damiana Pieragostino
    Centro Studi sull Invecchiamento Ce S I, Fondazione G d Annunizio, Chieti, Italy
    J Proteomics 73:579-92. 2010
    ..Apolipoprotein A-IV and complement C3 protein fragments, transthyretin and the oxidized isoforms in different apolipoprotein species represent the major molecular features of such a degradation pattern...
  10. doi Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis
    Damiana Pieragostino
    Research Centre on Aging Ce S I, University G d Annunzio of Chieti Pescara, Chieti, Italy
    Proteomics 13:1002-9. 2013
    ..Moreover, we found low levels of free T4 in CSF of multiple sclerosis patients, suggestive of a potential role of these modifications in T4 transport into the brain...
  11. doi Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study
    Alessandra Lugaresi
    Department of Oncology and Neuroscience, University G D Annunzio, Chieti, Italy
    Clin Neuropharmacol 31:167-72. 2008
    ..This study investigated the satisfaction of patients with relapsing-remitting MS treated with IFN-beta-1a (Rebif) by the autoinjection system, Rebiject...
  12. ncbi Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis
    Carla Iarlori
    Department of Oncology and Neuroscience, Neuroimmunology Unit, University G D Annunzio, Via dei Vestini, I 66013, Chieti, Italy
    J Neuroimmunol 123:170-9. 2002
    ..Logistic regression analysis shows that MCP-1 production is significantly modified by treatment. Further studies are needed to clarify the role of MCP-1 in MS...
  13. ncbi Cleavage of cystatin C is not associated with multiple sclerosis
    Piero Del Boccio
    Centro Studi Sull Invecchiamento, Fondazione G D Annunzio, Chieti, Italy
    Ann Neurol 62:201-4; discussion 205. 2007
    ..We conclude that the use of the 12.5 kDa product of cystatin C in cerebrospinal fluid might lead to a fallacious diagnosis of multiple sclerosis. Preanalytical validation procedure is mandatory for proteomics investigations...